 |
SEONGNAM, South Korea, June 13, 2025 /PRNewswire/ — PharmaResearch announced on June 13 that its board of directors has approved a corporate spin-off, resulting in the formation of two distinct entities: PharmaResearch Holdings, which will remain as the surviving entity focused on investment and governance, and PharmaResearch, a newly established operating company that will continue to lead the aesthetics business.
The decision is part of a broader strategy to enhance operational efficiency and sharpen business focus by separating investment and commercial functions. PharmaResearch Holdings will serve as the group’s control tower, managing subsidiaries, directing M&A activities, and pursuing long-term value creation. The new PharmaResearch will concentrate on its core business areas—including medical devices, pharmaceuticals, and cosmetics—with the goal of accelerating growth in the global aesthetics market.
The spin-off ratio is 0.7427944 for PharmaResearch Holdings and 0.2572056 for the new PharmaResearch. Following the spin-off, total assets are expected to reach KRW 580.2 billion (approx. USD 427.2 million) for PharmaResearch Holdings and KRW 219.5 billion (approx. USD 161.6 million) for PharmaResearch.
The proposed spin-off will be finalized following shareholder approval at an extraordinary general meeting scheduled for October. If approved, the effective date will be November 1, 2025, followed by re-listing procedures for both entities.
A company spokesperson commented, “This spin-off will allow us to sharpen our competitive edge in each business segment and respond more swiftly to evolving global market dynamics. Transitioning to a holding company structure will establish a strong foundation for sustainable growth and deliver greater long-term value to our shareholders.”
In a separate move to enhance shareholder value, PharmaResearch has also announced that it will cancel all of its treasury shares on June 20.
ข่าวที่เกี่ยวข้อง
- AUDI E7X Debuts with Ambilight EC Smart Dimming Panoramic Roof
- Isomorphic Labs secures $2.1 Billion funding to scale its AI drug design engine
- Zetaris Appoints Two Industry Heavyweights to Accelerate Global Growth
- Porton Advanced and Dark Horse Consulting Group Announce Memorandum of Understanding Providing A Streamlined Path to Conducting IITs in China
